Payment & Shipping Terms:
|Molecular Weight:||883.01||Molecular Formular:||C49H54N8O8|
|Quality Standard:||Enterprise Standard||CAS#:||1377049-84-7|
Velpatasvir Pharmaceutical Raw Materials Active Pharmaceutical Ingredients
Treat all six main HCV genotypes in the first scheme, velpatasvir, a new drug, and was the first to treat all six main type of HCV.
The FDA's drug evaluation and research center director of antimicrobial products in said: "the approval for a broad range of patients with chronic hepatitis c provides a treatment and treatment options."Priority review.
velpatasvir, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.
In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3.
Sofosbuvir works by interfering with the activity of an enzyme (NS5B) used by HCV-infected cells. Velpatasvir works by interfering with another HCV enzyme called NS5A.
Overall, 99% of participants who took sofosbuvir + velpatasvir were cured of hepatitis C 12 weeks after the cessation of therapy. Such high cure rates occurred regardless of the genotype or subtype of HCV. This cure, referred to as a sustained virological response, is written as SVR12. None of the participants who received placebo were cured.
|Category||Pharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.|
|Shelf life||2 years|
|Usage||Velpatasvir is used for treat Hepatitis C virus.|
|Storage||Velpatasvir should be stored in a well-closed container at low temperature, keep away from moisture, heat and light.|
Chemical structure :